These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16317670)

  • 1. Trends in health care resource use for hepatitis C virus infection in the United States.
    Grant WC; Jhaveri RR; McHutchison JG; Schulman KA; Kauf TL
    Hepatology; 2005 Dec; 42(6):1406-13. PubMed ID: 16317670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection.
    Tencer T; Friedman HS; Li-McLeod J; Johnson K
    J Manag Care Pharm; 2007; 13(9):790-8. PubMed ID: 18062730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of hospital care of liver disease associated with hepatitis C in the United States.
    Kim WR; Gross JB; Poterucha JJ; Locke GR; Dickson ER
    Hepatology; 2001 Jan; 33(1):201-6. PubMed ID: 11124837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004.
    Myers RP; Liu M; Shaheen AA
    Can J Gastroenterol; 2008 Apr; 22(4):381-7. PubMed ID: 18414713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States.
    Younossi ZM; Otgonsuren M; Henry L; Arsalla Z; Stepnaova M; Mishra A; Venkatesan C; Hunt S
    J Viral Hepat; 2015 Feb; 22(2):137-45. PubMed ID: 24813350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden associated with patients diagnosed with hepatitis C.
    McCombs JS; Yuan Y; Shin J; Saab S
    Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospitalizations due to hepatitis C in Los Angeles County, 2007-2009: case characteristics and factors associated with mortality.
    Sie L; Gatto NM; Bancroft E
    J Viral Hepat; 2013 Sep; 20(9):628-37. PubMed ID: 23910647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States.
    Galbraith JW; Donnelly JP; Franco RA; Overton ET; Rodgers JB; Wang HE
    Clin Infect Dis; 2014 Sep; 59(6):755-64. PubMed ID: 24917659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005-2013.
    Johnson NB; Hayes LD; Brown K; Hoo EC; Ethier KA;
    MMWR Suppl; 2014 Oct; 63(4):3-27. PubMed ID: 25356673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospitalizations and costs associated with hepatitis C and advanced liver disease continue to increase.
    Xu F; Tong X; Leidner AJ
    Health Aff (Millwood); 2014 Oct; 33(10):1728-35. PubMed ID: 25288416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam.
    Matser A; Urbanus A; Geskus R; Kretzschmar M; Xiridou M; Buster M; Coutinho R; Prins M
    Addiction; 2012 Mar; 107(3):614-23. PubMed ID: 21919987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Renal Disease on Patients with Hepatitis C: A Retrospective Analysis of Disease Burden, Clinical Outcomes, and Health Care Utilization and Cost.
    Solid CA; Peter SA; Natwick T; Guo H; Collins AJ; Arduino JM
    Nephron; 2017; 136(2):54-61. PubMed ID: 28214902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The costs of not treating hepatitis C virus infection in injecting drug users in New Zealand.
    Sheerin IG; Green FT; Sellman JD
    Drug Alcohol Rev; 2003 Jun; 22(2):159-67. PubMed ID: 12850902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone.
    Braitstein P; Li K; Kerr T; Montaner JS; Hogg RS; Wood E
    AIDS Care; 2006 Oct; 18(7):690-3. PubMed ID: 16971276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018-2040.
    McDonald SA; Azzeri A; Shabaruddin FH; Dahlui M; Tan SS; Kamarulzaman A; Mohamed R
    Appl Health Econ Health Policy; 2018 Dec; 16(6):847-857. PubMed ID: 30145775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Burden of Untreated HCV Infection in Hospitalized Inmates: a Hospital Utilization and Cost Analysis.
    Wurcel AG; Burke DJ; Wang JJ; Engle B; Noonan K; Knox TA; Kim AY; Linas BP
    J Urban Health; 2018 Aug; 95(4):467-473. PubMed ID: 30027427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burden of illness of hepatitis C from a managed care organization perspective.
    Armstrong EP; Charland SL
    Curr Med Res Opin; 2004 May; 20(5):671-9. PubMed ID: 15140332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The burden of hepatitis C in the United States.
    Kim WR
    Hepatology; 2002 Nov; 36(5 Suppl 1):S30-4. PubMed ID: 12407574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National estimates of case-mix, mortality, and economic outcomes among inpatient HIV/AIDS mono-infection and hepatitis C co-infection cases in the US.
    Pham T; Rathbun RC; Keast S; Nesser N; Farmer K; Skrepnek G
    J Eval Clin Pract; 2019 Oct; 25(5):806-821. PubMed ID: 30485617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health Care Utilization, Patient Costs, and Access to Care in US Adults With Eczema: A Population-Based Study.
    Silverberg JI
    JAMA Dermatol; 2015 Jul; 151(7):743-52. PubMed ID: 25738422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.